MediciNova (NASDAQ:MNOV) Research Coverage Started at StockNews.com

Stock analysts at StockNews.com started coverage on shares of MediciNova (NASDAQ:MNOV) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

MediciNova Trading Down 4.4 %

Shares of NASDAQ:MNOV opened at $1.73 on Tuesday. The firm has a market cap of $84.85 million, a price-to-earnings ratio of -10.18 and a beta of 0.75. MediciNova has a 1 year low of $1.12 and a 1 year high of $2.16. The business has a fifty day simple moving average of $1.73 and a 200 day simple moving average of $1.49.

MediciNova (NASDAQ:MNOV) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. On average, sell-side analysts forecast that MediciNova will post -0.23 EPS for the current year.

About MediciNova

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.